Floatz logo

plx2853

Diffuse Large B Cell Lymphoma

Opna Bio LLCPhase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
73/ 100

Competitive context

271 Active assets in the Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

plx2853 is also rated in:

uveal melanomaDormant
CC
Indicative ·
45 / 100
View asset →
Refractory Acute Myeloid Leukemia (AML)Dormant
C
Indicative ·
38 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →